Drugs Made In America Acquisition II Corp(DMII) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
AI-drawn chart patterns are for reference only.
Full metrics table
| Index | - | P/E | 36.96 | EPS (ttm) | 0.28 | Insider Own | 22.15% | Shs Outstand | 63.7M | Perf Week | -0.1% |
| Market Cap | 0.65B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 49.6M | Perf Month | 0.39% |
| Enterprise Value | 0.65B | PEG | - | EPS next Q | - | Inst Own | 74.8% | Short Float | 0.2% | Perf Quarter | 0.79% |
| Income | 0.02B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.72 | Perf Half Y | 1.69% |
| Sales | 0.00B | P/B | 1.3 | EPS next 5Y | - | ROA | 3.47% | Short Interest | 0.10M | Perf YTD | 3.33% |
| Book/sh | 7.86 | P/C | 5430.47 | EPS past 3/5Y | - | ROE | 3.6% | 52W High | -0.97% ($10.33) | Perf Year | - |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | 3.53% | 52W Low | 3.75% ($9.86) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 0.09% 0.09% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.01 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.22 | EPS Q/Q | 10457.14% | Profit Margin | - | RSI (14) | 56.34 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.22 | Sales Q/Q | - | SMA20 | 0.08% ($10.22) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 0.35% ($10.19) | Rel Volume | 3.6 | Prev Close | $10.25 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 1.56% ($10.07) | Avg Volume(3M) | 0.14M | Price | $10.23 |
| IPO | 2025/12/3 | Option/Short | No/Yes | Trades | 283 | Volume | 486,888 | Change | -0.2% |
💊 Drugs Made in America Acquisition II (DMII) is a special purpose acquisition company (SPAC) launched with the pharmaceutical industry as its merger target. It operates under a blank-check structure, placing the funds raised through its IPO in a trust account while seeking a merger partner that is a pharmaceutical or biotech company with a proven business model.
Over the past 1 year, on the higher side
1% below its 1-year high.
Traded more than usual. That is 360% of its average volume.
Company yardsticks do not fit here, so profitability, valuation and earnings are left out. The other verdicts still apply.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 74.8%.
Tap to view numbers
It ranks #547 of 1430 in the industry
Based on market cap of $652M.
FAQ
DMII belongs to the Financial sector and operates in the Shell Companies industry.
The market cap of DMII is approximately $652M, ranking 2,819 within its sector.
DMII has a P/E ratio of approximately 37.0x, which can be used to assess its valuation relative to the Financial sector average.
DMII has recorded a 52-week high of $10.33 and a low of $9.86.